Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice

PURPOSE: Two chimeric antigen receptor T-cell (CAR-T) therapies have been approved in the United States (USA) in 2017 and Europe (EU) in 2018: axicabtagene ciloleucel and tisagenlecleucel. They contain the patient’s own T cells, which are extracted, genetically modified, and reinfused. Alongside the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonaldo, Giulia, Montanaro, Nicola, AlbertoVaccheri, Motola, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Pharmacoepidemiology and Prescription
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275491/
https://www.ncbi.nlm.nih.gov/pubmed/33608749
http://dx.doi.org/10.1007/s00228-021-03106-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275491/
https://www.ncbi.nlm.nih.gov/pubmed/33608749
http://dx.doi.org/10.1007/s00228-021-03106-z

Ejemplares similares